PDA

View Full Version : Biotechnology News

Pages : 1 [2]
  1. New direction for Alzheimer's research?
  2. Merck's cholesterol drug wins European OK
  3. Introgen shares dive after report questions drug’s efficacy
  4. ViroPharma to buy Lev for $442M
  5. Minnesota blueprints new complex for biomedical research
  6. Side effects force Neurogen to suspend dosing
  7. Amgen releases positive denosumab results
  8. In fresh blow, Roche shutters HIV research program
  9. GSK inks $3.25B insomnia pact with Actelion
  10. Alcon axes eye program
  11. Pharming shares spike on positive Rhucin data
  12. Repros data highlights pain relief in Proellex trial
  13. FDA goes neutral with new response letters
  14. Schering-Plough fertility drug aces Phase III
  15. Invitrogen gets breast cancer test approval
  16. Medivation touts Phase II data on Huntington’s therapy
  17. Copaxone disappoints at higher dose
  18. Introgen axes staff as focus shifts to commercialization
  19. Amgen drug positive in cancer trial
  20. FDA panel backs added risk review on diabetes drugs
  21. Three technologies that could change the world
  22. Introgen files first gene therapy for FDA approval
  23. UCB files for Cimzia RA approval in Europe
  24. Positive data paves way for ThromboGenics trial
  25. Flurizan flunks its Phase III Alzheimer’s test
  26. Labopharm hopes high for tramadol despite rejection
  27. Biopharma sees tougher FDA approval process
  28. Merck, Schering-Plough end respiratory collaboration
  29. Ardea touts IIa data
  30. Quark prepares for human trials of siRNA therapy
  31. FDA considers new trial standard for diabetes drugs
  32. FDA delays review of Eli Lilly’s would-be blockbuster
  33. GTC shares jump on $257M ATryn pact
  34. AtheroGenics releases diabetes data
  35. FDA lifts clinical hold on YM therapy
  36. Discovery Labs shares dive on FDA delay
  37. Australia approves bird flu vaccine
  38. FDA committee backs Centocor psoriasis drug
  39. Phase III data paves way for Theratechnologies’ NDA
  40. Biotech drug sales grow 12.5% in 2007
  41. Scientists lament HIPAA's impact on new research projects
  42. Alzheimer's vaccine results boost Elan, Wyeth
  43. J&J psoriasis drug may carry cancer risk
  44. Sanofi: Acomplia demonstrates better glucose control
  45. DPP-4 inhibitors get spotlight at ADA meeting
  46. Vertex shares rise on positive data for telaprevir
  47. Hollis-Eden touts new diabetes data; Nastech announces positive insulin report
  48. Committee votes to back GSK/Ligand's Promacta
  49. SPOTLIGHT: Pertuzumab slows breast cancer in study
  50. Bayer, J&J tout rivaroxaban data
  51. Alfacell stock takes a hit on Onconase data
  52. Expert panel underwhelmed by GSK's Promacta
  53. Merck's osteoporosis drug performs in Phase II
  54. Amgen's D-mab beats Fosamax in trial
  55. United posts positive data for inhaled PAH drug
  56. Wyeth gets approvable letter for bazedoxifene
  57. Progenics, Wyeth drug fails late-stage trial
  58. FDA OKs Adolor's Entereg in first approval
  59. Merck shelves study of cholesterol drug
  60. Aflibercept misses endpoint in mid-stage study
  61. Ipsen clears FDA hurdle, gains $25M for Reloxin BLA
  62. FDA picking up the pace on '08 approvals
  63. Roche posts new data backing Actemra for RA
  64. Talecris' antibody drug gets priority review
  65. FDA delays Entereg decision
  66. FDA approves Lilly's ADHD drug Strattera
  67. Analyst predicts a long delay for Merck's Cordaptive
  68. FDA rejections signal tougher developers standards
  69. Purdue jumps ahead in pain drug race
  70. Inspire abandons allergy spray
  71. Rituxan fails (again) in late-stage lupus trial
  72. Cholesterol drug delay signals new FDA standards
  73. FDA approves Wyeth, Progenics drug
  74. Biotech's next big opportunity: Follow-ons?
  75. SPOTLIGHT: Glaxo appraises Sirtris' potential
  76. ALSO NOTED: FDA approves UCB's Cimzia; MacroChem acquires Virium; and much more...
  77. Renovo reports positive Juvista data
  78. Alpharma withdraws painkiller NDA
  79. PBMs making big bucks off specialty drugs
  80. Avastin, Erbitux battle for lung cancer market
  81. Wyeth, ViroPharma drops Hep C drug
  82. Pfizer, Avant ink $440M cancer vax deal
  83. SPOTLIGHT: Novartis touts new MS data
  84. Introgen gets positive Phase III Advexin data
  85. Eisai drug flunks Parkinson's trial
  86. Big Biotech emerges as a shelter in economic storm
  87. Finding no magic for 'Merlin,' Sir Evans shifts focus
  88. Symbollon warns of trouble after Phase III failure
  89. U.S. R&D headcount tumbles in key categories
  90. Boehringer boasts of late-stage drug potential
  91. Antigenics gets world's first cancer vaccine approval
  92. Pfizer halts tremelimumab development
  93. ALSO NOTED: Targeted Genetics buys Sirna's share of program; Indevus in $21M licensing deal;Atrium Innovations sells di
  94. SPOTLIGHT: Organogenesis plans expansion
  95. Can Big Pharma effectively develop new drugs?
  96. FDA approves GSK's Rotarix
  97. Study finds big gaps in clinical trial process
  98. Pfizer halts Phase III cancer trial on poor results
  99. SPOTLIGHT: Biotech sector poised for growth
  100. SPOTLIGHT: Investors fund vaccination programs
  101. Boehringer wins approval in anti-clotting drug race
  102. Presidio snags preclinical hep C program for $108M
  103. SPOTLIGHT: Cancer drug flunks Phase III
  104. Rare disease puts Phase III vax trial on hold
  105. Wyeth, Progenics drug flunks Phase III trial
  106. GSK successful in Phase III inflammation trial
  107. Amgen wins a key approval for platelet therapy
  108. Wyeth, Progenics drug flunks trial
  109. Phase III data sinks Keryx's diabetes drug
  110. Breakthrough reported in flu vaccine research
  111. Alkermes: Lilly may dump inhaled insulin program
  112. SPOTLIGHT: Worst Pharma Stocks of 2007
  113. Morphotek licenses anti-cancer antibody